Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin as Adjunctive Therapy in High-Grade Glioma
2024-520228-28-00Phase 2Authorised
- Sponsor
- University of Milano-Bicocca
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in glioblastoma (GBM), sponsored by University of Milano-Bicocca. Primary endpoint: Progression-free survival at approximately 6 months. Planned start Feb 2025; status: authorised.
02
Drugs
metformin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-520228-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520228-28-00.